“This innovative approach supports our strategy to apply Medigene’s 3S TCRs into new TCR-guided modalities, such as TCR-TCEs and now TCR-NKs, to create additional value for both patients and our shareholders,” said Selwyn Ho, CEO of Medigene. “Expanding our TCR-guided therapies to include NK cells aligns with our commitment to developing off-the-shelf, highly specific, and effective immunotherapies for cancer treatment.”

Dave Mehalick, CEO of COEPTIS stated, “Partnering with NUBURU marks a significant step in COEPTIS’ journey toward pioneering innovative technology solutions. By harnessing the power of NexGen’s AI-driven capabilities, we are poised to not only enhance our own operational efficiencies but also redefine how businesses engage with their clients in the rapidly evolving defense and security landscape. This collaboration underscores our commitment to fostering growth through advanced technological integrations.”

Title

AION Labs Announces 2025 Global Call for AI Applications

Description

AION Labs partners with BioMed X to launch an AI-driven platform for innovative medical device applications in 2025.

“Clinicians need a reliable, data-driven tool to make informed treatment decisions,” added Dr. Mark Kidd, Laboratory Director at Wren Laboratories. “With NETest 2.0, we’ve significantly enhanced diagnostic precision, allowing for improved patient surveillance and better treatment outcomes.”

“The CHMP’s recommendation for approval of VYJUVEK is an exciting step towards our goal of delivering the first ever corrective therapy to DEB patients across Europe,” said Suma Krishnan, President of Research and Development at Krystal Biotech. “The CHMP’s support for a broad label, including treatment of patients from birth and the option of patient or caregiver administration at home, are also fantastic outcomes for the DEB patients we aim to serve, broadening access and reducing barriers to starting on and staying on therapy.”

As the world’s first and currently only approved phosphate absorption inhibitor, Tenapanor Hydrochloride Tablets has been officially approved in China, ushering in a new era of multi-mechanism synergistic phosphate control and offering new hope for patients with hyperphosphatemia on hemodialysis in China.